A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers

Trial Profile

A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Moxifloxacin; Talampanel
  • Indications Amyotrophic lateral sclerosis; Bacterial infections; Drug-induced dyskinesia; Epilepsy; Glioma
  • Focus Pharmacodynamics
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 31 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top